Back to News
Market Impact: 0.48
AstraZeneca's TAGRISSO Achieves 8-Year Survival Milestone In Early-Stage EGFR- Mutated Lung Cancer
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
AstraZeneca's TAGRISSO delivered an unprecedented eight-year overall-survival benefit in early-stage EGFR-mutated non-small cell lung cancer. The result is the longest survival reported in a global Phase III trial for this setting, strengthening TAGRISSO's clinical profile and potential commercial position in early-stage lung cancer.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.82
Ticker Sentiment
AZN0.95
More News
- Why GM and Hilton are ditching the NYSE for Nasdaq
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- RBC Capital cuts Sprouts Farmers Market stock rating on margin concerns